They showed that in high expressing PPARGC1A ccRCCs, immune-related signalling and epithelial mesenchymal transition pathways were the most enriched, while in low expressing tumours, metabolic pathways were highly enriched. The gene discussed is PPARGC1A; the disease is neoplasm.